Abstract Number: 2624 • 2016 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibodies Titers Are Independently Modulated By Disease Activity and Synthetic or Biologic Dmards in a Seropositive Early Arthritis Population
Background/Purpose: Early introduction of some biologic (b) DMARDs has been proposed to reduce anti-citrullinated protein antibodies (ACPA) titers in clinical trials settings. However, less information…Abstract Number: 2625 • 2016 ACR/ARHP Annual Meeting
Safety of Multiple Retreatments with Rituximab in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis
Background/Purpose: Data are very limited concerning the safety of multiple retreatments with rituximab (RTX) in rheumatoid arthritis in common practice. Methods: This is a multicenter…Abstract Number: 2626 • 2016 ACR/ARHP Annual Meeting
Soluble CD206 Plasma Levels Decreases with Treatment and Reflects Anti-Tnfa Discontinuation in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial joints and infiltration by activated macrophages. TNFa is a central…Abstract Number: 2627 • 2016 ACR/ARHP Annual Meeting
The Effect of Fostamatinib with Methotrexate on Circulating Biomarkers of Synovium, Cartilage and Bone Metabolism: Potential Utility for Clinical Development Decision Making in Rheumatoid Arthriti
Background/Purpose: Fostamatinib was developed for the treatment of RA and improved signs and symptoms of RA 1, but did not improve modified Total Sharp Score…Abstract Number: 2628 • 2016 ACR/ARHP Annual Meeting
Retention of Use and Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: A Patient Record Assessment in a Compassionate Use Programme in South Africa, a Tuberculosis Endemic Country
Background/Purpose: South Africa is a tuberculosis (TB) endemic country having one of the highest TB infection rates in the world with close to 1000 cases…Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting
Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry
Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…Abstract Number: 2630 • 2016 ACR/ARHP Annual Meeting
EBV Load Quantification in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis Treated By Abatacept and Tocilizumab
Background/Purpose: For twenty years, the Epstein-Barr Virus (EBV) has been suspected to contribute to Rheumatoid Arthritis (RA). Immunity against EBV is impaired in RA. RA…Abstract Number: 2631 • 2016 ACR/ARHP Annual Meeting
Trends and Factors Associated with Use of Biologic Agents As Monotherapy Among US Patients with Rheumatoid Arthritis
Background/Purpose: For patients with rheumatoid arthritis (RA) receiving a biologic disease-modifying antirheumatic drug (bDMARD), the current standard of care is to use the bDMARD concurrently…Abstract Number: 2632 • 2016 ACR/ARHP Annual Meeting
Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis
Background/Purpose : This analysis assessed the effects of baseline patient characteristics on the response to baricitinib treatment in patients with rheumatoid arthritis (RA) and incomplete…Abstract Number: 2633 • 2016 ACR/ARHP Annual Meeting
Effect of Different Biologic Agents on Lipid Profile in Rheumatoid Arthritis
Background/Purpose: o examine any change between different biologic agents on lipid profile of RA patients. Methods: Patients affected by RA, according to the 2010 EULAR/ACR…Abstract Number: 2634 • 2016 ACR/ARHP Annual Meeting
Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis
Background/Purpose: Mavrilimumab is an anti-GM-CSF receptor Ab that has recently demonstrated clinical efficacy in Phase 2 studies in rheumatoid arthritis (RA) patients. Predictive biomarkers to…Abstract Number: 2635 • 2016 ACR/ARHP Annual Meeting
Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA
Background/Purpose: The Patient Reported Outcomes Measurement Information System (PROMIS) is an NIH initiative to develop patient-reported outcome measures (PROs) for use across chronic conditions. PROMIS…Abstract Number: 2636 • 2016 ACR/ARHP Annual Meeting
No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
Background/Purpose: Tapering of biologics in rheumatoid arthritis (RA) is based on a trial-and-error disease activity guided strategy, because it is not known in advance which…Abstract Number: 2637 • 2016 ACR/ARHP Annual Meeting
Clinical Trials Aiming to Prevent the Development of Rheumatoid Arthritis Cannot Detect Prevention without Adequate Risk Stratification; A Trial Performed in UA-Patients As Example
Background/Purpose: Prevention of rheumatoid arthritis (RA) was the aim of several clinical trials performed in undifferentiated arthritis (UA). Overall these trials had negative results. As…Abstract Number: 2638 • 2016 ACR/ARHP Annual Meeting
In Vitro Expansion of Treg By Adaimumab Predicts Clinical Response to Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Regulatory T cells (Treg) are potent suppressors of immune responses and are considered a pivotal element in resolving inflammation and autoimmunity. We have previously…
ACR Meeting Abstracts